Bluejay Diagnostics, Inc. (BJDX) has implemented a 1-for-4 reverse stock split of its common stock, which became effective on November 3, 2026. This action, approved by the Board of Directors, consolidates the company's shares, and the stock will trade on a post-split basis on the Nasdaq Capital Market under the existing symbol "BJDX".
Key Details
- Effective Date: The reverse stock split was effective at 12:01 a.m. ET on November 3, 2026, with post-split trading beginning at market open on the same day.
- Split Ratio & Share Impact: Every four issued and outstanding shares of common stock were converted into one share. This reduced the number of outstanding shares from approximately 4,468,051 to approximately 1,117,013.
- Terms: The par value of $0.0001 per share remains unchanged. No fractional shares will be issued; stockholders will receive a cash payment instead. The company's stock will trade under a new CUSIP number, 095633707.